Duke University at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Duke University takes part in 4 sessions at CTAD 2026 in Boston. Its program spans real-world lecanemab practice, plasma markers of ARIA and AI tools for trial recruitment. Its work also covers an APOE-targeted epigenome therapy built on single-cell findings.

OrganizationCTAD 2026 Attendance
Duke University
Durham, North Carolina
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Application of Data Mining and AI LLM Tools to enhance recruitment for an MCI clinical trial (P134)
Digital assessment and AI · Trial design and endpoints
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Clinical Practice Outcomes with Lecanemab for Alzheimer’s Disease (P152)
Anti-amyloid and anti-tau therapies · Real-world data and access
Poster
Wed Nov 18
7:15am–5:30pm
Plasma Biomarkers of ARIA identified through NULISAseq Multiplex Profiling (P290)
Blood and CSF biomarkers · Anti-amyloid and anti-tau therapies
Poster
Wed Nov 18
7:15am–5:30pm

Explore the full CTAD 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full CTAD 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Duke University

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction